Get started Log in

4565 — Nxera Pharma Share News

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapMomentum Trap

Market Cap
¥123bn
Enterprise Value
¥159bn
Revenue
¥30bn

9-MTH group results (IFRS)
11/11/2022 06:30
6-MTH group results (IFRS)
10/08/2022 07:30
Brief: Sosei Heptares And Abbvie Enter New Multi-Target Collaboration To Discover, Develop And Commercialize Novel Medicines Targeting Neurological Diseases
02/08/2022 24:16
Q1 group results (IFRS)
13/05/2022 07:30
2021 group results (IFRS)
16/02/2022 23:00
2021 group results (IFRS)
10/02/2022 06:30
Brief: Sosei Heptares Announces Antitrust Clearance Of License Agreement With Neurocrine Biosciences
23/12/2021 23:29
Brief: Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
16/12/2021 12:37
Brief: Neurocrine Biosciences And Sosei Heptares Announce Collaboration To Develop Novel Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders
22/11/2021 16:59
9-MTH group results (IFRS)
11/11/2021 06:30
6-MTH group results (IFRS)
12/08/2021 07:30
Brief: Sosei Says Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist With Biohaven
23/06/2021 08:06
Q1 group results (IFRS)
12/05/2021 07:30
Brief: Sosei Heptares Spin-Off Company Orexia Therapeutics Merged Into Newly Created Centessa Pharmaceuticals
16/02/2021 12:45
2020 group results (IFRS)
12/02/2021 06:30
Press Digest: British Business - Dec 21
21/12/2020 01:53
Sosei, GSK agree to develop inflammatory bowel disease treatment
20/12/2020 23:30
9-MTH group results (IFRS)
11/11/2020 06:30
Japan's Sosei allies with ex-Novartis team to develop neurological drug pipeline
02/11/2020 12:00
6-MTH group results (IFRS)
13/08/2020 07:30